Effects of evolving lipid-lowering drugs on carbohydrate metabolism

被引：2

作者：

Tsimihodimos, V. ^{[1
]}

Elisaf, M. ^{[1
]}

机构：

[1] Univ Ioannina, Sch Med, Dept Internal Med, Niarchou Ave, GR-45110 Ioannina, Greece

来源：

DIABETES RESEARCH AND CLINICAL PRACTICE | 2018年 / 137卷

关键词：

Antisense oligonucleotides; PCSK9; inhibitors; Apolipoprotein CIII inhibitors; CETP inhibitors; Lp(a); LOW-DENSITY-LIPOPROTEIN; OF-FUNCTION MUTATIONS; ALPHA/DELTA AGONIST GFT505; APOLIPOPROTEIN C-III; TARGETING APOLIPOPROTEIN(A); GLUCOSE-HOMEOSTASIS; INSULIN SENSITIVITY; DOUBLE-BLIND; BETA-CELLS; HIGH-RISK;

D O I：

10.1016/j.diabres.2017.12.012

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The understanding that statins reduce but not eliminate the cardiovascular risk associated with disturbed lipid metabolism and the existence of forms of dyslipidemia that are unresponsive or only partially responsive to statins have led to the development of many novel lipid-lowering drugs. Accumulating evidence suggests that the interplay between carbohydrate and lipid metabolism is bidirectional. Thus, any intervention that affects lipid metabolism has the potential to influence the homeostasis of glucose. In this review we summarize the available data on the effects of the evolving lipid-lowering drugs on carbohydrate metabolism. (C) 2017 Elsevier B.V. All rights reserved.

引用

页码：1 / 9

页数：9

共 50 条

[41] Mipomersen: a lipid-lowering agent with a novel mechanism of action
Gouni-Berthold, Ioanna
Rizzo, Manfredi
Berthold, Heiner K.
CLINICAL LIPIDOLOGY, 2013, 8 (03) : 279 - 282
[42] Targeted Strategy in Lipid-Lowering Therapy
Dayar, Ezgi
Pechanova, Olga
BIOMEDICINES, 2022, 10 (05)
[43] Prediction of response to lipid-lowering treatments
Tomlinson, Brian
Chan, Paul
Liu, Zhong-Min
EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2018, 3 (06): : 335 - 337
[44] Lipid-lowering medications for children and adolescents
Miller, Melissa L.
Wright, Chanin C.
Browne, Barry
JOURNAL OF CLINICAL LIPIDOLOGY, 2015, 9 (05) : S67 - S76
[45] Renal Safety Assessment of Lipid-Lowering Drugs: Between Old Certainties and New Questions
Tramontano, Daniele
Bini, Simone
Maiorca, Carlo
Di Costanzo, Alessia
Carosi, Martina
Castellese, Jacopo
Arizaj, Ina
Commodari, Daniela
Covino, Stella
Sansone, Giorgia
Minicocci, Ilenia
Arca, Marcello
D'Erasmo, Laura
DRUGS, 2025,
[46] Systematic Review: Evaluating the Effect of Lipid-Lowering Therapy on Lipoprotein and Lipid Values
Rosenson, Robert S.
Underberg, James A.
CARDIOVASCULAR DRUGS AND THERAPY, 2013, 27 (05) : 465 - 479
[47] Associations between lipid-lowering drugs and pregnancy and perinatal outcomes: a Mendelian randomization study
Wang, Runfang
Zhao, Jing
Li, Li
Huo, Yan
JOURNAL OF HYPERTENSION, 2024, 42 (04) : 727 - 734
[48] Association of lipids and lipid-lowering drugs with peripheral arterial disease: A Mendelian randomization study
Tao, Mengjun
Zhang, Yuanxiang
Li, Qi
Feng, Xuebing
Ping, Cheng
JOURNAL OF CLINICAL LIPIDOLOGY, 2024, 18 (06) : e968 - e976
[49] Evaluating the Lipid-Lowering Effects of α-lipoic Acid Supplementation: A Systematic Review
Erickson, Nicole
Zafron, Michelle
Harding, Scott, V
Marinangeli, Christopher P. F.
Rideout, Todd C.
JOURNAL OF DIETARY SUPPLEMENTS, 2020, 17 (06) : 753 - 767
[50] Lipid-lowering effects of polydatin from Polygonum cuspidatum in hyperlipidemic hamsters
Du, Jian
Sun, Lian-Na
Xing, Wei-Wei
Huang, Bao-Kang
Jia, Min
Wu, Jin-Zhong
Zhang, Hong
Qin, Lu-Ping
PHYTOMEDICINE, 2009, 16 (6-7) : 652 - 658

← 1 2 3 4 5 →